HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults. HYQVIA is for subcutaneous use only. Safety and efficacy of chronic use of Recombinant Human Hyaluronidase in HYQVIA have not been established in conditions other than PI.


Less time spent infusing.1*
More time for daily activities.

*Every 3 or 4 weeks.

Once a month* infusions. Reliable protection against infection.1,2

For people with PI, there is more to life than managing their treatment schedule. HYQVIA offers monthly* SCIG infusions to help patients maximize time between infusions.1

*Every 3 or 4 weeks.

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is a monthly SCIG treatment option1

Calendar icon.
Up to 28 days*
between infusions
Clock icon.
2 hour infusion1
Median infusion time was
2.08 (0.83-4.68) hours in the clinical trial1†

*Every 3 or 4 weeks.

HYQVIA was studied in a prospective, open-label, non-controlled, multicenter clinical trial conducted to determine the efficacy, tolerability, and pharmacokinetics (PK) of HYQVIA in patients with primary immunodeficiency (PI). The primary outcome measure was the annualized rate of acute serious bacterial infections (ASBI), which was evaluated in 83 patients over a median treatment duration of 366 days (42 to 507 days).

Review Important Safety Information, including adverse reactions.

What makes HYQVIA different?

Recombinant Human Hyaluronidase in HYQVIA locally, temporarily, and reversibly modifies the hyaluronan in the subcutaneous tissue, helping increase the dispersion and absorption of IG.1

Subcutaneous tissue with conventional SCIG.

Subcutaneous tissue with conventional SCIG

Up to 60 mL/site with conventional SCIG3

  • The subcutaneous tissue contains hyaluronan, a gel-like substance, which causes resistance to fluid flow1,4,5
  • Hyaluronan is depolymerized by the naturally occurring enzyme hyaluronidase1
  • Approximately 1/3 of hyaluronan is replaced in the body daily5

SCIG = subcutaneous immune globulin

Recombinant Human Hyaluronidase.

Recombinant Human Hyaluronidase

Recombinant Human Hyaluronidase1

  • Mimics the natural depolymerization process of hyaluronan
  • Results in a temporary increase in the permeability of the subcutaneous tissue
Subcutaneous Tissue with HYQVIA.

Subcutaneous Tissue with HYQVIA

Up to 600 mL/site with HYQVIA1

  • Increased dispersion and absorption of the IG component of HYQVIA
  • Allows a full monthly* dose via a single infusion site
  • Permeability of the subcutaneous tissue is restored within 24 to 48 hours

*Every 3 or 4 weeks.

A second site can be used at the discretion of the physician and patient based on tolerability and total volume. If a second site is used, administer half the total volume of Recombinant Human Hyaluronidase of HYQVIA in each site.

HYQVIA Clinical Trial

See the HYQVIA efficacy
results from the clinical trial.

Learn more

HYQVIA dosing

See details of HYQVIA dosing, including
the ramp-up schedule.

Learn more


See Important Safety Information, including
drug interactions.

Learn more
  1. HYQVIA [prescribing information]. Lexington, MA: Baxalta US Inc.
  2. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Food and Drug Administration website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-efficacy-and-pharmacokinetic-studies-support-marketing-immune-globulin-intravenous-human. Accessed May 28, 2019.
  3. CUVITRU [prescribing information]. Lexington, MA: Baxalta US Inc.
  4. Wasserman RL, Melamed I, Stein MR, et al; and IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-957.
  5. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-440.